Blood pressure and metabolic effects of nebivolol compared with hydrochlorothiazide and placebo in hypertensive patients with impaired glucose tolerance or impaired fasting glucose

Trial Profile

Blood pressure and metabolic effects of nebivolol compared with hydrochlorothiazide and placebo in hypertensive patients with impaired glucose tolerance or impaired fasting glucose

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 May 2011

At a glance

  • Drugs Hydrochlorothiazide; Lisinopril; Losartan; Nebivolol
  • Indications Hypertension
  • Focus Therapeutic Use
  • Sponsors Forest Laboratories
  • Most Recent Events

    • 24 May 2011 Results presented at the 26th Annual Scientific Meeting of the American Society of Hypertension.
    • 22 Sep 2010 Actual end date added to 1 Jul 2010 as reported by ClinicalTrials.gov.
    • 22 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top